Merus (MRUS) – Research Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of Merus (NASDAQ: MRUS) recently:

• 10/8/2025 – Merus had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 10/6/2025 – Merus had its “market perform” rating reaffirmed by analysts at Leerink Partners. They now have a $97.00 price target on the stock, up previously from $95.00.
• 10/5/2025 – Merus was downgraded by analysts at Leerink Partnrs from a “strong-buy” rating to a “hold” rating.
• 9/30/2025 – Merus was downgraded by analysts at UBS Group AG from a “buy” rating to a “neutral” rating. They now have a $97.00 price target on the stock, up previously from $72.00.
• 9/30/2025 – Merus was downgraded by analysts at BMO Capital Markets from an “outperform” rating to a “hold” rating.
• 9/30/2025 – Merus had its “equal weight” rating reaffirmed by analysts at Barclays PLC. They now have a $97.00 price target on the stock, down previously from $112.00.
• 9/30/2025 – Merus was downgraded by analysts at Barclays PLC from an “overweight” rating to an “equal weight” rating. They now have a $97.00 price target on the stock, down previously from $112.00.
• 9/30/2025 – Merus had its “neutral” rating reaffirmed by analysts at Guggenheim. They now have a $97.00 price target on the stock, down previously from $109.00.
• 9/30/2025 – Merus had its “market perform” rating reaffirmed by analysts at Lifesci Capital. They now have a $97.00 price target on the stock.
• 9/29/2025 – Merus was downgraded by analysts at HC Wainwright from a “buy” rating to a “neutral” rating. They now have a $97.00 price target on the stock, down previously from $135.00.
• 9/29/2025 – Merus was downgraded by analysts at Canaccord Genuity Group Inc. from a “buy” rating to a “hold” rating. They now have a $97.00 price target on the stock, up previously from $67.00.
• 9/29/2025 – Merus was downgraded by analysts at William Blair from a “strong-buy” rating to a “hold” rating.
• 9/29/2025 – Merus was downgraded by analysts at Truist Financial Corporation from a “buy” rating to a “hold” rating. They now have a $97.00 price target on the stock, up previously from $88.00.
• 9/29/2025 – Merus had its “equal weight” rating reaffirmed by analysts at Wells Fargo & Company. They now have a $97.00 price target on the stock, up previously from $95.00.
• 9/29/2025 – Merus was downgraded by analysts at Needham & Company LLC from a “buy” rating to a “hold” rating. They now have a $96.00 price target on the stock.
• 9/29/2025 – Merus was downgraded by analysts at Lifesci Capital from a “strong-buy” rating to a “hold” rating.
• 9/29/2025 – Merus was downgraded by analysts at Guggenheim from a “strong-buy” rating to a “hold” rating.
• 9/29/2025 – Merus was downgraded by analysts at Wells Fargo & Company from an “overweight” rating to an “equal weight” rating. They now have a $97.00 price target on the stock, up previously from $95.00.
• 9/29/2025 – Merus was downgraded by analysts at Citigroup Inc. from a “buy” rating to a “neutral” rating. They now have a $97.00 price target on the stock, down previously from $101.00.
• 9/27/2025 – Merus had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/17/2025 – Merus is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $112.00 price target on the stock.
• 9/16/2025 – Merus is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $112.00 price target on the stock.
• 8/25/2025 – Merus was given a new $90.00 price target on by analysts at Industrial Alliance Securities.
• 8/25/2025 – Merus is now covered by analysts at Alliance Global Partners. They set a “buy” rating and a $90.00 price target on the stock.

Insider Buying and Selling

In related news, COO Peter B. Silverman sold 25,000 shares of the firm’s stock in a transaction dated Thursday, July 17th. The shares were sold at an average price of $60.00, for a total value of $1,500,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.70% of the stock is currently owned by insiders.

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.